Publikation
Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes
Wissenschaftlicher Artikel/Review - 01.04.2007
Schimke Katrin-Elisabeth, Davis Timothy M E
Bereiche
PubMed
Zitation
Schimke K, Davis T. Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes. Current opinion in investigational drugs (London, England : 2000) 2007; 8:338-44.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Current opinion in investigational drugs (London, England : 2000) 2007; 8
Veröffentlichungsdatum
01.04.2007
ISSN (Druck)
1472-4472
Seiten
338-44
Kurzbeschreibung/Zielsetzung
Daiichi Sankyo Inc is developing rivoglitazone, an insulin sensitizer with peroxisome proliferator-activated receptor gamma agonistic activity, for the potential treatment of type 2 diabetes. By March 2006, phase I/III clinical trials were underway in the US and the EU.